Business Overview
American HealthCare Capital is pleased to exclusively introduce a premier, award-winning investment banking and strategic advisory platform focused entirely on the global life sciences and healthcare sectors. Established in 2011, this strategy-led, boutique firm possesses institutional-grade execution capabilities. The platform specializes in ushering clinical, diagnostic, medical device, digital health, and biopharmaceutical technologies from initial concept through to successful liquidity events, effectively creating a broad offering that spans middle-market, science-intensive mandates through to larger, cross-border healthcare transactions. Its unique hybrid advisory/banking model, combined with deep scientific, clinical, and market expertise, has established the company as a thought-leading firm driving a strong deal flow.
The company commands high operational barriers to entry, operating as a fully licensed, FINRA-registered Broker-Dealer where all active transaction team members hold required regulatory individual certifications. The platform features an elite operational model anchored by senior industry veterans holding advanced scientific, financial, and clinical credentials (PhDs, MDs, JDs, and MBAs). This multidisciplinary depth enables the firm to speak the language of corporate boards, institutional investors, and global strategic acquirers alike, securing premium closed-deal valuations across middle-market transactions. In addition, a substantial body of peer reviewed publications, authored by the company’s personnel, has established the company’s strong specialist brand and reinforced its position as a thought leader in the segment.
Operational & Service Profile
The company’s core modalities include corporate development, buy-side and sell-side M&A execution, private equity/debt capital placement, asset divestitures, and highly specialized long-term strategic partnering advisory. The firm structures its client engagements via two primary contractually protected corporate fee streams: flat monthly advisory fees and transaction success fees. The business model features exceptional stability, as the majority of these recurring flat monthly advisory fees directly cover the firm’s fixed operating costs.
The platform currently services 16 active corporate clients under exclusive advisory agreements. Geographically, the client roster is highly diversified, with the majority of clients based in the U.S. and a meaningful presence across international markets. The client portfolio features remarkable safety, with no single client accounting for more than 10% of the firm’s total revenue. Originations are driven organically by inbound inquiries and relationship networks rather than outbound marketing.
Financial Performance & Margin Drivers
The business showcases exceptional, debt-free financial health with multi-million-dollar cash flows. Investment banking revenues are inherently deal-driven, resulting in predictable variations based on transaction close dates. Over the last three audited fiscal years, total annual receipts consistently ranged between $5.69 million and $7.73 million.
Current fiscal year 2026 projections reflect an explosive growth trajectory, annualizing at $8,353,341 in gross revenue and yielding an expected $3,674,067 in EBITDA. This represents a premier 44.0% projected EBITDA margin, fueled by a powerful combination of predictable monthly baseline advisory retainers and accelerated mid-year transaction success fees.
Exit Plan
The principal founders are committed to executing a structured, comprehensive transitional hand-off. To preserve long-term client board relationships and ensure uninterrupted compliance over-active FINRA transactions, management is completely open to negotiating a customized post-closing transition or advisory arrangement with the acquiring group.
Asking Price
The final purchase price will be determined through discussions with qualified buyers based on market feedback and overall deal structure.